ACW | Small Caps

Actinogen Medical ASX ACW cognitive improvement Xanamem XanaHES Alzheimer’s disease neurological

Actinogen Medical announces ‘breakthrough’ study results for Alzheimer’s drug Xanamem

October 1, 2019

Actinogen Medical (ASX: ACW) has announced “breakthrough” results from its XanaHES higher dose safety study first initiated last year. The results reaffirm the foundational hypothesis that reducing...

Actinogen Medical ASX ACW Phase 2 Alzheimer's disease trial results fail dementia

Actinogen Medical phase two Alzheimer’s clinical trial disappoints

May 7, 2019

Biotech company Actinogen Medical (ASX: ACW) has reported a mixed bag of results including some disappointing outcomes from its XanADu phase two clinical trial treating patients with mild dementia due...

Actinogen Medical ASX ACW US biotech investor Alzheimer’s XanADu study

Actinogen Medical attracts US biotech investor as Alzheimer’s XanADu study remains on track

May 23, 2018

Actinogen Medical (ASX: ACW) has received a double-shot of positive news earlier today after the biotech company received the all-clear from the Data Safety and Monitoring Board (DSMB) to continue its...

Actinogen Medical ASX ACW XanADu treat Alzheimer’s disease

Actinogen moves towards XanADu starting line to treat Alzheimer’s disease

March 21, 2018

Biotech company Actinogen Medical (ASX: ACW) has confirmed that it has obtained half of the required patients in order to conduct its landmark Phase 2 clinical trial of Xanamem, a drug candidate to tr...

RECENT POSTS

Vintage Energy ASX VEN Toolachee Patchawarra carbon dioxide gas Nangwarry

Vintage Energy encounters a number of gas shows during drilling of Vali-2

May 7, 2021

Invex Therapeutics ASX IXC Presendin Exenatide contract manufacturing organisation CMO

Invex Therapeutics narrows its search for preferred CMO to manufacture commercial quantities of Presendin

May 7, 2021

QSuper superannuation income pension retirement

Super income solutions are finally arriving

May 7, 2021

Strategic Elements ASX SOR Eastern Goldfields Regional Prison robotic security vehicle site acceptance

Strategic Elements subsidiary achieves site acceptance testing of autonomous security vehicle

May 6, 2021

STOCK SUMMARY

INVESTOR TOOLS

FOLLOW US

HOT TOPICS

QSuper superannuation income pension retirement

Super income solutions are finally arriving

May 7, 2021

Non-bank sector ASX lenders lending BNPL buy now pay later

Who’s who in the burgeoning listed non-bank sector

May 5, 2021

Banks dividends rebound ASX ANZ MQG NAB QFN WBC 2021

Banks are back as dividends rebound

May 4, 2021

TRENDING POSTS

Banks dividends rebound ASX ANZ MQG NAB QFN WBC 2021

Banks are back as dividends rebound

QMines ASX QML IPO copper gold Mt Chalmers Queensland

QMines debuts on ASX with $11.5m to fund copper-gold strategy at Mt Chalmers

CBD PBS medicinal cannabis Australia subsidy ASX IHL Dravet syndrome epilepsy

First subsidised CBD oil shows promise for Incannex Healthcare’s own medical cannabis drugs in Australia

Lithium stocks ASX

Lithium stocks on the ASX: The Ultimate Guide

Strategic Elements ASX SOR Eastern Goldfields Regional Prison robotic security vehicle site acceptance

Strategic Elements subsidiary achieves site acceptance testing of autonomous security vehicle

Non-bank sector ASX lenders lending BNPL buy now pay later

Who’s who in the burgeoning listed non-bank sector

QSuper superannuation income pension retirement

Super income solutions are finally arriving

Creso Pharma Halucenex Nucro-Technics efficacy synthetic liquid psilocybin treatment-resistant PTSD ASX CPH

Creso Pharma acquisition target Halucenex to test efficacy of synthetic liquid psilocybin for use in treatment-resistant PTSD

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.